https://mindmedicinelaw.com/briefing/safety-concerns-in-expanding-ketamine-clinics-and-delivery-20260622-15471The Psychedelic Journalen2026-06-22T15:05:25.371456+00:00Safety Concerns in Expanding Ketamine Clinics and Deliveryketamine clinics, at-home delivery, patient safety, regulatory oversight, mental health treatment, ketamine therapy, FDA guidelines, treatment efficacy, safety concerns, clinical trialshttps://mindmedicinelaw.com/briefing/definium-s-lsd-formula-achieves-top-results-in-depression-trial-20260622-15468The Psychedelic Journalen2026-06-22T15:04:51.724032+00:00Definium's LSD Formula Achieves Top Results in Depression TrialDefinium Pharmaceuticals, LSD depression trial, psychedelic research, mental health treatment, serotonin receptors, regulatory approvals, treatment-resistant depression, psychedelic compoundshttps://mindmedicinelaw.com/briefing/new-trial-design-framework-for-psychedelic-research-20260621-15388The Psychedelic Journalen2026-06-22T15:05:02.385556+00:00New Trial Design Framework for Psychedelic Researchpsychedelic research, trial design, ketamine, psilocybin, treatment-resistant depression, compound-race-pathology, psychiatric conditions, post-viral conditions, autoimmune conditions, clinical trialshttps://mindmedicinelaw.com/briefing/psilocybin-s-epigenetic-impact-on-alcohol-use-disorder-20260621-15145The Psychedelic Journalen2026-06-21T22:04:17.743293+00:00Psilocybin's Epigenetic Impact on Alcohol Use Disorderpsilocybin, epigenetics, alcohol use disorder, psychedelic therapy, gene expression, clinical trials, neuroscience, personalized medicine, treatment outcomes, regulatory frameworkshttps://mindmedicinelaw.com/briefing/emerging-psychedelic-therapies-for-bipolar-depression-20260620-15394The Psychedelic Journalen2026-06-22T15:05:37.424940+00:00Emerging Psychedelic Therapies for Bipolar Depressionpsilocybin, ketamine, bipolar disorder, treatment-resistant depression, psychedelic therapies, clinical trials, neuromodulation, mental health, pharmacology, psychiatric carehttps://mindmedicinelaw.com/briefing/psilocybin-reduces-cocaine-use-clinical-trial-insights-20260620-15310The Psychedelic Journalen2026-06-21T22:04:06.959459+00:00Psilocybin Reduces Cocaine Use: Clinical Trial Insightspsilocybin, cocaine use reduction, clinical trial, psychedelic therapy, substance use disorder, Filament Health, neuroscience, market dynamics, therapeutic potential, regulatory challengeshttps://mindmedicinelaw.com/briefing/limited-effects-of-low-dose-lsd-in-adhd-clinical-trial-insights-20260620-15057The Psychedelic Journalen2026-06-21T15:04:43.116398+00:00Limited Effects of Low-Dose LSD in ADHD: Clinical Trial Insightslow-dose LSD, ADHD treatment, neuropsychological effects, temporal processing, clinical trials, psychedelic research, cognitive domains, mental health, psychedelic therapies, LSD studyhttps://mindmedicinelaw.com/briefing/ketamine-assisted-psychotherapy-for-ptsd-review-insights-20260619-15457The Psychedelic Journalen2026-06-22T15:05:12.814140+00:00Ketamine-Assisted Psychotherapy for PTSD: Review Insightsketamine-assisted psychotherapy, PTSD treatment, systematic review, meta-analysis, psychedelic therapy, clinical guidelines, treatment predictors, mental health policy, neuroscience, public healthhttps://mindmedicinelaw.com/briefing/understanding-death-wishes-in-older-adults-a-multidimensional-approach-20260619-15027The Psychedelic Journalen2026-06-21T22:04:54.125982+00:00Understanding Death Wishes in Older Adults: A Multidimensional Approachdeath wishes, older adults, narrative review, psychological factors, social influences, legal frameworks, clinical practice, geriatric psychiatry, existential sensitivity, ageing societyhttps://mindmedicinelaw.com/briefing/canmat-2023-guidelines-on-treatment-resistant-depression-20260619-15068The Psychedelic Journalen2026-06-21T22:04:45.783007+00:00CANMAT 2023 Guidelines on Treatment-Resistant DepressionCANMAT 2023 guidelines, treatment-resistant depression, ketamine, esketamine, psychedelic therapies, mental health treatment, pharmacological strategies, non-pharmacological treatments, clinical trials, long-term efficacyhttps://mindmedicinelaw.com/briefing/phytomedicines-and-antipsychotic-induced-eps-research-insights-20260619-15071The Psychedelic Journalen2026-06-21T22:04:34.580587+00:00Phytomedicines and Antipsychotic-Induced EPS: Research Insightsphytomedicines, extrapyramidal symptoms, antipsychotic drugs, schizophrenia treatment, herbal medicines, clinical trials, neurobiological mechanisms, KEAP1/Nrf2 pathway, monoaminergic neurotransmission, neuroinflammationhttps://mindmedicinelaw.com/briefing/exploring-the-gut-spinal-cord-axis-in-spinal-cord-injury-20260619-15072The Psychedelic Journalen2026-06-21T22:04:25.907103+00:00Exploring the Gut-Spinal Cord Axis in Spinal Cord Injuryspinal cord injury, gut microbiota, neuroinflammation, central nervous system, microbiota-derived metabolites, clinical trials, therapeutic strategies, bidirectional communication, gut-spinal cord axis, secondary inflammatory responseshttps://mindmedicinelaw.com/briefing/psychedelic-use-motives-among-us-young-adults-20260619-15028The Psychedelic Journalen2026-06-21T15:05:22.640137+00:00Psychedelic Use & Motives Among US Young Adultspsychedelic use, young adults, mental health, microdosing, nonmedical use, sociodemographics, adverse childhood events, psilocybin, MDMA, LSDhttps://mindmedicinelaw.com/briefing/psilocybin-s-role-as-a-conserved-morphogenetic-signal-20260619-15058The Psychedelic Journalen2026-06-21T15:05:12.179599+00:00Psilocybin's Role as a Conserved Morphogenetic Signalpsilocybin, intercellular signaling, morphogenetic signal, psychedelic research, therapeutic applications, neuroplasticity, evolutionary biology, 5-HT2A receptors, archetypal integrationhttps://mindmedicinelaw.com/briefing/psilocybin-s-ancient-signaling-implications-for-therapy-20260619-15059The Psychedelic Journalen2026-06-21T15:05:03.053660+00:00Psilocybin's Ancient Signaling: Implications for Therapypsilocybin, ancient signaling, dual-drift model, psychedelic therapy, clinical trials, evolutionary biology, 5-HT2A receptors, archetypal integration, neural processes, public healthhttps://mindmedicinelaw.com/briefing/ank3-biomarker-discovery-for-liafensine-in-trd-implications-20260619-15069The Psychedelic Journalen2026-06-21T15:04:52.265125+00:00ANK3 Biomarker Discovery for Liafensine in TRD: ImplicationsANK3 gene, liafensine, treatment-resistant depression, biomarker discovery, precision medicine, pharmacogenomics, triple reuptake inhibitor, psychiatric treatment, genome-wide association study, clinical trialshttps://mindmedicinelaw.com/briefing/eeg-based-ai-model-revolutionizes-depression-diagnosis-20260618-15031The Psychedelic Journalen2026-06-21T15:05:39.162613+00:00EEG-Based AI Model Revolutionizes Depression DiagnosisEEG-based AI model, depression diagnosis, MSTANet, clinical applicability, mental health screening, neuroscience, public health, AI in healthcare, psychiatric diagnostics, signal processinghttps://mindmedicinelaw.com/briefing/polysubstance-use-and-mental-health-insights-and-implications-20260617-14530The Psychedelic Journalen2026-06-20T22:03:37.870310+00:00Polysubstance Use and Mental Health: Insights and Implicationspolysubstance use, mental health disorders, trauma-informed care, substance use disorders, integrated treatment, phenomenological study, psychedelic research, co-occurring conditions, emotional pain management, environmental influenceshttps://mindmedicinelaw.com/briefing/exercise-and-fluoxetine-enhance-neuroplasticity-in-rats-20260617-14531The Psychedelic Journalen2026-06-20T22:03:25.899063+00:00Exercise and Fluoxetine Enhance Neuroplasticity in Ratsexercise, fluoxetine, neuroplasticity, depression treatment, Wistar rats, multimodal approach, antidepressants, psychiatric treatment, clinical trials, biomarkershttps://mindmedicinelaw.com/briefing/cannabinoids-and-anxiety-promising-results-future-research-20260617-14560The Psychedelic Journalen2026-06-20T22:03:15.755974+00:00Cannabinoids and Anxiety: Promising Results, Future Researchcannabinoids, anxiety relief, young adults, cannabis strains, endocannabinoid system, dosage, self-reported data, clinical trials, mental health, policy implicationshttps://mindmedicinelaw.com/briefing/zebrafish-larvae-in-anxiety-drug-screening-implications-20260617-14584The Psychedelic Journalen2026-06-20T22:03:05.366181+00:00Zebrafish Larvae in Anxiety Drug Screening: Implicationszebrafish larvae, anxiety drug screening, behavioral assays, molecular markers, serotonergic compounds, psilocybin research, anxiolytic profiles, psychedelic researchhttps://mindmedicinelaw.com/briefing/directed-human-connectome-advancing-brain-hierarchy-studies-20260617-14532The Psychedelic Journalen2026-06-20T22:02:54.798335+00:00Directed Human Connectome: Advancing Brain Hierarchy Studiesdirected human structural connectome, brain network organization, psychedelic research, brain mapping, large-scale brain simulations, directionality in connectomes, neuroscience advancements, personalized digital brain modelshttps://mindmedicinelaw.com/briefing/at-home-ketamine-therapy-for-burnout-emerging-insights-20260616-14565The Psychedelic Journalen2026-06-20T22:03:47.256060+00:00At-Home Ketamine Therapy for Burnout: Emerging Insightsat-home ketamine therapy, burnout treatment, ketamine-assisted therapy, non-clinical settings, public health, clinical guidelines, market opportunities, mental health, real-world studyhttps://mindmedicinelaw.com/briefing/crispr-enhances-psilocybin-production-in-e-coli-20260613-15458The Psychedelic Journalen2026-06-22T15:05:48.230907+00:00CRISPR Enhances Psilocybin Production in E. coliCRISPR, psilocybin production, E. coli, DMT biosynthesis, genetic engineering, psychedelic research, clinical trials, biotechnology, therapeutic applications, regulatory implications